BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer
January 13, 2016Research and Development MSD, immunotherapy, keytruda, pembrolizumab
Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …
Big pharma joins President Obama’s cancer ‘moonshot’
January 13, 2016Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot
Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …
Cell and Gene Therapy World: PCI Pharma Services expert to present on cold chain challenges
January 13, 2016Medical Communications
Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at Cell and Gene Therapy World (January …
Senate panel approves Dr Robert Califf as FDA commissioner
January 13, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Robert Califf, FDA, FDA commissioner, Senate
A senate panel has approved president Obama’s nominee Dr Robert Califf to lead the FDA by a clear majority, although …
Takeda and enGene partner to develop gastro drugs
January 13, 2016Research and Development Takeda
Takeda is teaming up with Canadian biotech enGene to develop novel therapies for specialty gastrointestinal (GI) diseases, using enGene’s ‘gene …
MedImmune and UCSF team up to research RAI treatments
January 13, 2016Research and Development MedImmune, Precision Medicine, University of California San Francisco, autoimmunity
AstraZeneca’s biologics R&D arm MedImmune and the University of California, San Francisco (UCSF) have announced a new research collaboration focused …
MSD to acquire Scottish firm IOmet Pharma
January 12, 2016Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology
US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …
Eisai submits new cancer combo to EMA for approval
January 12, 2016Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib
Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
SMC approves first ever treatment for genetic kidney disease
January 12, 2016Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
Former Novartis site to be developed into science park
January 12, 2016Manufacturing and Production Employment, Jobs, Life science, Novartis, West Sussex, science park
Work has begun to transform a 20-acre site that formerly housed Novartis, in West Sussex, into a world renowned centre …
AstraZeneca and MedImmune in oncology research deals
January 12, 2016Manufacturing and Production, Research and Development AstraZeneca, Incyte, MedImmune, Moderna Therapeutics
AstraZeneca and its biologics arm MedImmune are launching new agreements with partner companies, to develop new targets for cancer, and …
Pfizer raised 100 US drug prices 1 January
January 12, 2016Manufacturing and Production, Sales and Marketing Allergan, Drug pricing, Lyrica, Pfizer, ibrance, tax inversion
Drugs giant Pfizer raised the prices of more than 100 of its drugs in the US on 1 January, in …
Mark Alles is new chief executive of Celgene
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles
Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …
The Pharmafocus debate: Can ultra-orphan drugs be made cheaper?
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, Duchenne Muscular Dystrophy, Translarne, access to medicines, ataluren, muscular dystrophy, rare disease, ultra orphan drugs, ultra-orphan drugs
The recent reimbursement wrangle between PTC Therapeutics and NICE, the UK healthcare watchdog, has once again raised difficult questions about …
Roche snaps up Tensha Therapeutics for up to $535m
January 12, 2016Manufacturing and Production, Research and Development Roche, Tensha Therapeutics
Roche has acquired Tensha Therapeutics, a privately-held company based in Cambridge, Massachusetts for up to $535 million.The deal that gives …
Genomics appoints Sekar Kathiresan as scientific advisory board chair
January 11, 2016Sales and Marketing genomics
Genomics has appointed Dr Sekar Kathiresan as chair of the company’s newly-formed scientific advisory board as chair, with immediate effect. Dr …
AbbVie tests new hepatitis C drug in Phase III trials
January 11, 2016Research and Development AbbVie, clinical trials, hepatitis C, phase III
AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …
Three appointments in AstraZeneca’s global media relations team
January 11, 2016Medical Communications AstraZeneca
Neil Burrows has joined as head of global media relations, following Esra Erkal-Paler’s promotion to head of global external communications.Burrows …
Shire and Baxalta reach $32 billion merger agreement
January 11, 2016Manufacturing and Production, Sales and Marketing Baxalta, Shire, mergers, mergers and acquisitions
One of the industry’s longest-running M&A sagas has finally reached a conclusion, with Shire and Baxalta announcing a $32 billion …
AbbVie begins late stage trials of rheumatoid arthritis drug
January 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis
AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
